Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 18/20 | 0.54 |
| ▸ | SLC5A1 | P13866 | 10/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3678607 | 0.85 | SLC5A2 (0.48) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL3680179 | 0.84 | SLC5A2 (0.49) | SLC5A2SLC5A1 | |
| SCHEMBL14315858 | 0.83 | SLC5A2 (0.54) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL3687397 | 0.83 | SLC5A2 (0.45) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL1539263 | 0.82 | SLC5A2 (0.54) | SLC5A2SLC5A1 | |
| SCHEMBL27771495 | 0.82 | SLC5A2 (0.44) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL3684973 | 0.82 | SLC5A2 (0.46) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL27771496 | 0.81 | SLC5A2 (0.46) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13683350 | 0.81 | SLC5A2 (0.49) | SLC5A2SLC5A1 | |
| SCHEMBL14235777 | 0.81 | KDM4E (0.45) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2676965-B1 | ARYL GLYCOSIDE COMPOUND, PREPARATION METHOD AND USE THEREOF | SHANGHAI YINGLI PHARM CO LTD (CN) | 2017-10-04 | — | — | EP | disclosed |
| US-8980829-B2 | Aryl glycoside compound, preparation method and use thereof | SHANGHAI YINGLI SCIENCE AND TECHNOLOGY CO., LTD (CN) | 2015-03-17 | — | — | US | disclosed |
| US-8980829-B2 | Aryl glycoside compound, preparation method and use thereof | SHANGHAI YINGLI SCIENCE AND TECHNOLOGY CO., LTD (CN) | 2015-03-17 | — | — | US | disclosed |
| US-8921412-B2 | C-aryl ansa SGLT2 inhibitors | GREEN CROSS CORPORATION (KR) | 2014-12-30 | — | — | US | disclosed |
| US-8921412-B2 | C-aryl ansa SGLT2 inhibitors | GREEN CROSS CORPORATION (KR) | 2014-12-30 | — | — | US | disclosed |
| US-8921412-B2 | C-aryl ansa SGLT2 inhibitors | GREEN CROSS CORPORATION (KR) | 2014-12-30 | — | — | US | disclosed |
| US-20140213642-A1 | NOVEL C-ARYL ANSA SGLT2 INHIBITORS | GREEN CROSS CORPORATION (KR) | 2014-07-31 | — | — | US | disclosed |
| US-20140213642-A1 | NOVEL C-ARYL ANSA SGLT2 INHIBITORS | GREEN CROSS CORPORATION (KR) | 2014-07-31 | — | — | US | disclosed |
| US-20140213642-A1 | NOVEL C-ARYL ANSA SGLT2 INHIBITORS | GREEN CROSS CORPORATION (KR) | 2014-07-31 | — | — | US | disclosed |
| WO-2012173410-A2 | NOVEL C-ARYL ANSA SGLT2 INHIBITORS | GREEN CROSS CORPORATION (KR) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012173410-A2 | NOVEL C-ARYL ANSA SGLT2 INHIBITORS | GREEN CROSS CORPORATION (KR) | 2012-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213642-A1 | NOVEL C-ARYL ANSA SGLT2 INHIBITORS | SLC5A2, SLC5A1, SLC2A1 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.